Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure-Reference-Cited by-同舟云学术

Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure

Published:2014-01-29 Issue:6 Volume:68 Page:731-742
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Karsenty G.¹,Baverstock R.²,Carlson K.²,Diaz D. C.³,Cruz F.⁴,Dmochowski R.⁵,Fulford S.⁶,Giannantoni A.⁷,Heesakkers J.⁸,Kaufmann A.⁹,Peyrat L.¹⁰,Thavaseelan J.¹¹,Dasgupta P.¹²

Affiliation:

1. Urology and Kidney Transplantation Aix Marseille University Marseille France

2. Division of Urology Department of Surgery vesia [Alberta Bladder Centre] University of Calgary Calgary AB Canada

3. Department of Urology University Hospital of the Canary Islands Canary Islands Spain

4. Department of Urology Hospital S. João and Faculty of Medicine of Porto PortoPortugal

5. Department of Urology Vanderbilt University Medical Center Nashville TN USA

6. Department of Urology The Golden Jubilee Spinal Injury Centre James Cook University Hospital Middlesbrough UK

7. Department of Urology and Andrology University of Perugia Perugia Italy

8. Department of Urology Radboud University Nijmegen MC Nijmegen The Netherlands

9. Center of Neuro‐Urology Kliniken Maria Hilf GmbH Mönchengladbach Germany

10. Department of Urology University Paris VI Paris France

11. Department of Neurourology and Urodynamics St John of God Murdoch Hospital and Medical Centre Perth Australia

12. MRC Centre for Transplantation NIHR Biomedical Research Centre Guy's Hospital King's College London London UK

Publisher

Hindawi Limited

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijcp.12360

Reference41 articles.

1. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society

2. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction

3. Defining overactive bladder: Epidemiology and burden of disease

4. Mirabegron: a review of recent data and its prospects in the management of overactive bladder

5. PannekJ.European Association of Urology. Guidelines on neurogenic lower urinary tract dysfunction 2011.http://www.uroweb.org/gls/pdf/17_Neurogenic%20LUTS.pdf(accessed June 2011).

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders;Pharmacological Reviews;2023-03-14

2. Intravesical botulinum toxin: Practice patterns from a survey of Canadian urologists;Canadian Urological Association Journal;2022-08-30

3. Postprocedural Pain Associated With 5 Versus 20 Intradetrusor Injections of onabotulinumtoxinA for Treatment of Overactive Bladder: A Multicenter Randomized Clinical Trial;Female Pelvic Medicine & Reconstructive Surgery;2022-05-12

4. Chemodenervation in Urology;Urologic Clinics of North America;2022-05

5. The First Injection: Rates of Urinary Retention in Women With Urgency Incontinence Treated With Intravesical OnabotulinumtoxinA Injection;Female Pelvic Medicine & Reconstructive Surgery;2021-01